Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Corn stigma polysaccharide combined drug preparation

A technology of corn silk polysaccharides and pharmaceutical preparations, which can be used in drug combination, drug delivery, antiviral agents, etc., and can solve problems such as unclear action targets

Inactive Publication Date: 2017-08-18
SHAOXING UNIVERSITY +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the current research has not clearly indicated the specific method by which it achieves the corresponding function, and basically only studies the function of the polysaccharide itself and rarely studies the combined efficacy of it and other drugs to carry out research, the main reason is that the specific role of the target is still unclear in the existing literature

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Corn stigma polysaccharide combined drug preparation
  • Corn stigma polysaccharide combined drug preparation
  • Corn stigma polysaccharide combined drug preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] The corn silk polysaccharide used in the following examples can be prepared by the following methods:

[0027] Collect fresh corn silk, wash and chop, soak 2-4 times with 80% edible alcohol, remove pigment and alcohol-soluble substances, dry, and then crush to obtain corn silk dry powder, pass through a 60-mesh sieve; take corn silk dry powder Add water according to the volume ratio of liquid to material 1:60, which is equivalent to adding 60mL of water to 1g of corn silk dry powder, then raise the temperature to raise the temperature of the system to about 95°C and reflux and extract for 3 hours under stirring. After the extraction is completed, control the rotation speed at 2500r / min Carry out centrifugation under the condition of 30min, repeat extraction 2 times, combine extract; Concentrate under reduced pressure to thick with rotary evaporator, obtain corresponding concentrate; Then add the chloroform-n-butanol (5: 1) The solution was shaken for 30 minutes, then ce...

Embodiment 2

[0031] The dosage form of the pharmaceutical preparation in this embodiment is sustained-release microspheres, and the drug sustained-release microspheres include the following components by weight:

[0032] Corn silk polysaccharide: 1.5; 2-deoxy-D-glucose: 0.5; gelatin: 10.

[0033] The specific preparation method of this slow-release microsphere can adopt following method to obtain:

[0034] It is prepared according to the volume of 100mL, processed by emulsification and cross-linking method, and corn silk polysaccharide and 2-DG are coated with gelatin as the carrier.

[0035]Select the raw materials according to the weight ratio of the above raw materials, select a small amount of gelatin and dissolve it in an appropriate amount of water at 60°C, then fully mix the corn silk polysaccharide and 2-DG, adjust the volume of the mixed solution to 100mL by adding the amount of water, And make the content of gelatin in the mixed solution be the gelatin of 10g in the 100mL mixed ...

Embodiment 3

[0037] The dosage form of the pharmaceutical preparation in this embodiment is sustained-release microspheres, and the drug sustained-release microspheres include the following components by weight:

[0038] Corn silk polysaccharide: 1.8; 2-deoxy-D-glucose: 0.4; gelatin: 12.

[0039] Wherein the corn silk polysaccharide mainly comprises the monosaccharide composition of following mass ratio:

[0040] The mass ratio of glucose: galactose: mannan: xylose: arabinose and rhamnose is 18:12:3:1:0.8:0.7.

[0041] The drug loading in the sustained-release microspheres was 9.0%.

[0042] The specific preparation method of the sustained-release microspheres is the same as that in Example 2, and will not be repeated here.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a corn stigma polysaccharide combined drug preparation and belongs to the technical field of drug application and aims to solve the problem of how to develop the hepatitis C virus resistant function of corn polysaccharide. The corn stigma polysaccharide combination drug preparation is prepared from components in parts by weight as follows: 1.3-1.8 parts of corn stigma polysaccharide, 0.3-0.7 parts of 2-deoxy-D-glucose, 5-15 parts of gelatin and 0-8 parts of a pharmaceutically acceptable carrier. The drug preparation can perform the functions of inducing IFN (interferon), down-regulating the content of cytomembrane cholesterol, influencing Jak-STAT antiviral signal channels and BAX-Bcl2 channels related with tumor apoptosis and promoting apoptosis of HCV infection cells by up-regulating apoptosis related protein and inhibiting anti-apoptosis protein.

Description

technical field [0001] The invention relates to a corn silk polysaccharide combined pharmaceutical preparation, which belongs to the technical field of pharmaceutical application. Background technique [0002] Hepatitis C virus (HCV) is the pathogen of hepatitis C and the main pathogenic factor leading to post-transfusion hepatitis and acute and chronic non-A and non-B hepatitis. Although, in recent years, with the development and application of genetic engineering technology, the development of new vaccines such as nucleic acid vaccines and synthetic peptide vaccines has increasingly become a major research hotspot in the medical field, but the stability and certainty of the nucleic acid vaccine effect are still unclear. There are still deficiencies. [0003] Although there are many types of adjuvants on the market, there are still very few drugs that can be used clinically. Therefore, the research and development of anti-hepatitis C drugs has a very good market value. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/715A61K31/7004A61K9/16A61P31/14A61P35/00
CPCA61K9/0002A61K9/1658A61K31/7004A61K31/715A61K2300/00
Inventor 陈佳玉柯瑞君杨林军陈佳琪罗心静
Owner SHAOXING UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com